NIP
ESPR

Nicholas Investment Partners’s Esperion Therapeutics ESPR Stock Holding History

Nicholas Investment Partners’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-235,855
Closed -$8.77M – 176
2020
Q3 		$8.77M Buy
235,855
+202,240
+602% +$8.01M 0.95% 36
2020
Q2 		$1.73M Sell
33,615
-52,503
-61% -$2.2M 0.35% 110
2020
Q1 		$2.71M Buy
86,118
+17,548
+26% +$926K 0.53% 80
2019
Q4 		$4.09M Buy
+68,570
New +$3.08M 0.42% 82
2019
Q1 		– Sell
-8,353
Closed -$384K – 216
2018
Q4 		$384K Sell
8,353
-65,718
-89% -$3.17M 0.04% 210
2018
Q3 		$3.29M Sell
74,071
-949
-1% -$43.6K 0.26% 149
2018
Q2 		$2.94M Buy
75,020
+6,272
+9% +$317K 0.21% 157
2018
Q1 		$4.97M Buy
+68,748
New +$5.05M 0.36% 84
2015
Q3 		– Sell
-60,630
Closed -$4.96M – 303
2015
Q2 		$4.96M Sell
60,630
-12,279
-17% -$1.2M 0.32% 106
2015
Q1 		$6.75M Buy
72,909
+32,805
+82% +$2.12M 0.42% 63
2014
Q4 		$1.62M Buy
40,104
+16,034
+67% +$491K 0.1% 262
2014
Q3 		$589K Buy
+24,070
New +$383K 0.04% 291

Other funds holding ESPR

BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $1.06B AUM 52.03% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Nicholas Investment Partners's ESPR Position: Q4 2020 in Review

Nicholas Investment Partners sold out of Esperion Therapeutics (ESPR) in Q4 2020, closing a stake of 235,855 shares — an estimated $8.77M sold.

Nicholas Investment Partners first reported a position in ESPR in Q3 2014 and held it in 12 quarters. The position peaked at $8.77M in Q3 2020. 157 funds tracked by Wall St. Rank hold ESPR as of Q4 2020.

  • Nicholas Investment Partners reported no remaining Esperion Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Nicholas Investment Partners sold 235,855 Esperion Therapeutics shares in Q4 2020, an estimated $8.77M.
  • Nicholas Investment Partners first reported a position in Esperion Therapeutics in Q3 2014 and held it in 12 quarters.
  • Nicholas Investment Partners's Esperion Therapeutics position peaked at $8.77M in Q3 2020.
  • 157 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q4 2020.

Based on Nicholas Investment Partners's 13F filing for Q4 2020, filed 11 Feb 2021.